Abstract
Human immunodeficiency virus (HIV) infection and antiretroviral therapy have been associated with non-alcoholic fatty liver disease (NAFLD), but few studies have evaluated whether HIV infection is an independent risk factor for the development of hepatic steatosis and advanced liver fibrosis. To study the prevalence and severity of hepatic steatosis and advanced fibrosis in people living with HIV and control outpatients. We conducted a cross-sectional analysis of relevant data from 875 pairs of individuals belonging to an HIV-dedicated outpatient clinic and an adult primary care clinic of an inner-city hospital. Hepatic Steatosis Index (HSI) and FIB-4 index were calculated as non-invasive measures of steatosis and fibrosis, respectively. A multivariate logistic regression analysis was performed to assess predictors of steatosis and advanced fibrosis. The prevalence of hepatic steatosis, determined by HSI ≥ 36, was higher in HIV-negative subjects (71.5% vs. 65.4%, p = 0.006). The prevalence of advanced fibrosis, determined by FIB-4 index ≥ 3.25, was higher in the HIV-positive group (7% vs. 1.7%, p < 0.001). Multivariable analysis did not identify HIV infection to be an independent risk factor for hepatic steatosis (p = 0.068) and advanced fibrosis. In this cohort, hepatic steatosis was more prevalent in non-HIV infected patients, while advanced fibrosis had a higher prevalence in people living with HIV. HIV infection was not found to be an independent risk factor for either hepatic steatosis or fibrosis.
Highlights
Hepatic steatosis is common in Human immunodeficiency virus (HIV) infection and is associated with poor outcomes and increased mortality [1]
Multivariable analysis did not identify HIV infection to be an independent risk factor for hepatic steatosis (p=0.068) and advanced fibrosis. In this cohort, hepatic steatosis was more prevalent in non-HIV infected patients, while advanced fibrosis had a higher prevalence in people living with HIV
Data on the prevalence and consequences of non-alcoholic fatty liver disease (NAFLD) in people living with HIV and on the risk factors for progression to fibrosis are limited
Summary
Hepatic steatosis is common in HIV infection and is associated with poor outcomes and increased mortality [1]. Advances in drug development have decreased the metabolic toxicity of antiretroviral therapy It is uncertain whether chronic HIV infection confers an increased risk of hepatic steatosis. Data on the prevalence and consequences of non-alcoholic fatty liver disease (NAFLD) in people living with HIV and on the risk factors for progression to fibrosis are limited. Obesity contributes to the development of steatosis, though most studies of NAFLD in people living with HIV do not stress this factor [5,6,7,8,9,10,11,12,13,14]. Human immunodeficiency virus (HIV) infection and antiretroviral therapy have been associated with non-alcoholic fatty liver disease (NAFLD), but few studies have evaluated whether HIV infection is an independent risk factor for the development of hepatic steatosis and advanced liver fibrosis
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
